BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, Xue F. Hormonal therapy in uterine sarcomas. Cancer Med 2019;8:1339-49. [PMID: 30897294 DOI: 10.1002/cam4.2044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang JY, Ma KS, Wang LT, Chiang CH, Yang SF, Wang CH, Wang PH. The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease. Cancers (Basel) 2023;15. [PMID: 36765791 DOI: 10.3390/cancers15030833] [Reference Citation Analysis]
2 Alswiket HM, Aldar HM, Alamry RF, Albahrani ZS, Alismail MA, Elghoneimy YA. Multidisciplinary Approach for a Rare Metastatic Low-Grade Endometrial Stromal Sarcoma to the Inferior Vena Cava and the Right Atrium. Cureus 2022;14:e32807. [PMID: 36694531 DOI: 10.7759/cureus.32807] [Reference Citation Analysis]
3 de Almeida BC, Dos Anjos LG, Dobroff AS, Baracat EC, Yang Q, Al-Hendy A, Carvalho KC. Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature. Biomedicines 2022;10:2567. [PMID: 36289829 DOI: 10.3390/biomedicines10102567] [Reference Citation Analysis]
4 Cao S, Liao X, Xu K, Xiao H, Shi Z, Zou Y, Li C, Hu Y, Yan S. Development and validation of tumor-size-stratified prognostic nomograms for patients with uterine sarcoma: A SEER database analysis. Cancer Med 2023;12:1339-49. [PMID: 35841316 DOI: 10.1002/cam4.5014] [Reference Citation Analysis]
5 Maccaroni E, Lunerti V, Agostinelli V, Giampieri R, Zepponi L, Pagliacci A, Berardi R. New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers 2022;14:921. [DOI: 10.3390/cancers14040921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mitra S, Lami MS, Ghosh A, Das R, Tallei TE, Fatimawali, Islam F, Dhama K, Begum MY, Aldahish A, Chidambaram K, Emran TB. Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications? Cancers (Basel) 2022;14:759. [PMID: 35159024 DOI: 10.3390/cancers14030759] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
7 Kaur EJ, Baruah U, Maheshwari A, Kataki AC. Hormone Replacement Therapy after Gynaecological Cancer. Fundamentals in Gynaecologic Malignancy 2022. [DOI: 10.1007/978-981-19-5860-1_26] [Reference Citation Analysis]
8 Dai Q, Xu B, Wu H, You Y, Wu M, Li L. The prognosis of recurrent low-grade endometrial stromal sarcoma: a retrospective cohort study. Orphanet J Rare Dis 2021;16:160. [PMID: 33827628 DOI: 10.1186/s13023-021-01802-8] [Reference Citation Analysis]
9 Akrivi S, Varras M, Anastasiadi Z, Pappa C, Vlachioti A, Varra VK, Varra FN, Balasi E, Akrivis C. Primary vulvar leiomyosarcoma localized in the Bartholin's gland area: A case report and review. Mol Clin Oncol 2021;14:69. [PMID: 33680460 DOI: 10.3892/mco.2021.2231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Mocellin S. Uterine Leiomyosarcoma. Soft Tissue Tumors 2021. [DOI: 10.1007/978-3-030-58710-9_250] [Reference Citation Analysis]
11 Akiyama M, Oonishi K, Aoki K, Koshiba H. A case of low-grade endometrial stromal sarcoma diagnosed after total laparoscopic hysterectomy: A case report. JAPANESE JOURNAL OF JSGOE 2021;37:135-140. [DOI: 10.5180/jsgoe.37.1_135] [Reference Citation Analysis]
12 Theodoridis T, Aivazi D, Zepiridis L, Vlachos N. Uterine Leiomyoma or Sarcoma? Handbook of Research on Oncological and Endoscopical Dilemmas in Modern Gynecological Clinical Practice 2021. [DOI: 10.4018/978-1-7998-4213-2.ch020] [Reference Citation Analysis]
13 Zhang H, Liu B, Shi X, Sun X. Long noncoding RNAs: Potential therapeutic targets in cardiocerebrovascular diseases. Pharmacol Ther 2021;221:107744. [PMID: 33181193 DOI: 10.1016/j.pharmthera.2020.107744] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
14 Rozonova OA, Artamonova EV, Kozlov NA. Expression of steroid hormone receptors in leiomyosarcoma of different anatomic localizations. Medicinskij alfavit 2020. [DOI: 10.33667/2078-5631-2020-20-49-53] [Reference Citation Analysis]
15 Ferrandina G, Aristei C, Biondetti PR, Cananzi FCM, Casali P, Ciccarone F, Colombo N, Comandone A, Corvo' R, De Iaco P, Dei Tos AP, Donato V, Fiore M, Franchi, Gadducci A, Gronchi A, Guerriero S, Infante A, Odicino F, Pirronti T, Quagliuolo V, Sanfilippo R, Testa AC, Zannoni GF, Scambia G, Lorusso D. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). Eur J Cancer 2020;139:149-68. [PMID: 32992154 DOI: 10.1016/j.ejca.2020.08.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Mindiola-Romero AE, Liu X, Dillon JL, Talarico M, Smith G, Zhang L, Linos K. Metastatic low-grade endometrial stromal sarcoma after 24 years: A case report and review of recent molecular genetics. Diagn Cytopathol 2021;49:E99-E105. [PMID: 32910526 DOI: 10.1002/dc.24601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Maenohara S, Fujimoto T, Okadome M, Sonoda K, Taguchi K, Saito T. Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report. Gynecol Oncol Rep 2020;34:100634. [PMID: 32953963 DOI: 10.1016/j.gore.2020.100634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Shushkevich A, Thaker PH, Littell RD, Shah NA, Chiang S, Thornton K, Hensley ML, Slomovitz BM, Holcomb KM, Leitao MM, Toboni MD, Powell MA, Levine DA, Dowdy SC, Klopp A, Brown J. State of the science: Uterine sarcomas: From pathology to practice. Gynecol Oncol 2020;159:3-7. [PMID: 32839026 DOI: 10.1016/j.ygyno.2020.08.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Bhatia K, Bhumika, Das A. Combinatorial drug therapy in cancer - New insights. Life Sci 2020;258:118134. [PMID: 32717272 DOI: 10.1016/j.lfs.2020.118134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
20 Hayashi T, Sano K, Ichimura T, Gur G, Yaish P, Zharhary D, Kanai Y, Tonegawa S, Yaegashi N, Konishi I. Candidate molecules as diagnostic biomarker for human uterine mesenchymal tumors. Ann Cytol Pathol 2020;5:054-057. [DOI: 10.17352/acp.000016] [Reference Citation Analysis]
21 Galon J, Bruni D. Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity 2020;52:55-81. [PMID: 31940273 DOI: 10.1016/j.immuni.2019.12.018] [Cited by in Crossref: 211] [Cited by in F6Publishing: 182] [Article Influence: 70.3] [Reference Citation Analysis]
22 Vaz J, Tian C, Richardson MT, Chan JK, Mysona D, Rao UN, Powell MA, Shriver CD, Hamilton CA, Casablanca Y, Maxwell GL, Darcy KM. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. Gynecol Oncol 2020;157:121-30. [PMID: 31954536 DOI: 10.1016/j.ygyno.2019.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
23 Zang Y, Dong M, Zhang K, Gao C, Guo F, Wang Y, Xue F. Hormonal therapy in uterine sarcomas. Cancer Med 2019;8:1339-49. [PMID: 30897294 DOI: 10.1002/cam4.2044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]